Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Glaxo (GSK) Misses on Q1 Earnings, Revenues Rise Y/Y

GlaxoSmithKline plc GSK, one of the largest health care companies, reshaped its business following the Mar 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. This UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products).

However, like many of its peers, Glaxo is facing challenges in the form of increasing competition, genericization and pricing pressure in major markets.

In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.

Glaxo’s performance has been pretty good with earnings surpassing expectations in three of the last four quarters. Overall, the company has delivered an average positive surprise of 4.34%.

Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Glaxo reported core earnings of 57 cents per American depositary share, missing our consensus estimate of 60 cents.

Revenues: Revenues were up 8% year over year at constant exchange rate (CER).

Key Stats: While the Consumer Healthcare and Vaccines segments were up 26% and 23%, respectively, the Pharmaceuticals segment was down 1% at CER.

2016 Guidance: Glaxo expects core earnings growth of 10–12% (at CER) in 2016.

Check back later for our full write up on this Glaxo’s earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research